{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T18:51:19Z","timestamp":1697309479581},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1985,6,1]],"date-time":"1985-06-01T00:00:00Z","timestamp":486432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[1985,6]]},"DOI":"10.1007\/bf02032282","type":"journal-article","created":{"date-parts":[[2005,8,10]],"date-time":"2005-08-10T14:23:17Z","timestamp":1123683797000},"page":"124-132","source":"Crossref","is-referenced-by-count":8,"title":["Correlation plasma levels, NSAID and therapeutic response"],"prefix":"10.1007","volume":"4","author":[{"given":"J. P.","family":"Famaey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02032282_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0163-7258(82)90052-3","volume":"16","author":"M.L.E. Orme","year":"1982","unstructured":"Orme, M.L'E. Plasma concentrations and therapeutic effect of anti-inflammatory and anti-rheumatic drugs. Pharmacol Ther, 1982, 16, 167\u2013180.","journal-title":"Pharmacol Ther"},{"key":"BF02032282_CR2","first-page":"1","volume-title":"Drug Treatment","author":"F. Sj\u00f6qvist","year":"1980","unstructured":"Sj\u00f6qvist, F., Borga, O., Orme, M.L'E. Fundamentals of clinical pharmacology. In: Drug Treatment 2nd ed. Editor: Avery, G.S. Adis Press, Australia, 1980, pp. 1\u201361.","edition":"2nd ed."},{"key":"BF02032282_CR3","first-page":"553","volume-title":"Clinics in rheumatic diseases","author":"A.R. Rhymer","year":"1979","unstructured":"Rhymer, A.R., Sulindac. In: Clinics in rheumatic diseases. Editor: Huskisson, E.C. Saunders Company Ltd., London, Philadelphia, Toronto. 1979, 5, 2, 553\u2013568."},{"key":"BF02032282_CR4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/jps.2600660403","volume":"66","author":"R.G. Child","year":"1977","unstructured":"Child, R.G., Osterberg, R.C., Sloboda, A.E., Tomcufick, A.S. A new anti-inflammatory analgesic arylalkanoic acid 3-(4-Biphenyl Carbonyl) Propionic acid, Fenbufen. Synthesis and structure-activity relationship of analogs. J Pharm Sci, (1977), 66, 466\u2013476.","journal-title":"J Pharm Sci"},{"key":"BF02032282_CR5","first-page":"716","volume":"30","author":"A.E. Sloboda","year":"1980","unstructured":"Sloboda, A.E., Tolman, E.L., Osterberg, A.C. Panagides, J. The pharmacological properties of Fenbufen. Arzneimittelforsch, 1980, 30, 716\u2013721.","journal-title":"Arzneimittelforsch"},{"key":"BF02032282_CR6","first-page":"40.1","volume-title":"Absorption, distribution and metabolism of drugs: biopharmaceutics and pharmacokinetics","author":"W.C. Bowman","year":"1980","unstructured":"Bowman, W.C., Rand, M.J. Textbook of Pharmacology. Chapter 40. Absorption, distribution and metabolism of drugs: biopharmaceutics and pharmacokinetics. 2nd ed., Blackwell Scientific Publication, Oxford-London-Edinburgh-Melbourne, 1980, pp. 40.1\u201340.58.","edition":"2nd ed."},{"key":"BF02032282_CR7","unstructured":"Gurwich, E., Raees, S., Skosey, J., Niazi S. Unbound plasma salicylate concentration in rheumatoid patients. Abstract C73, VIII Pan American Congress of Rheumatology, Washington D.C., Abstract Volume, 1982, p. S117."},{"key":"BF02032282_CR8","first-page":"717","volume":"7","author":"T.E. Poe","year":"1980","unstructured":"Poe, T.E., Mutchie, K.D., Saunders, G.H., Hanissian, A.S., Sotello, C.A. Total and free salicylate concentrations in juvenile rheumatoid arthritis. J Rheumatol, 1980, 7, 717\u2013723.","journal-title":"J Rheumatol"},{"key":"BF02032282_CR9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/cpt1976204464","volume":"20","author":"O. Borga","year":"1976","unstructured":"Borga, O., Odar-Cederlof, I., Ringberger, V.A., Norlin, A. Protein-binding of salicylates in uremic and normal plasma. Clin Pharmacol Ther, 1976, 20, 464\u2013475.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1172\/JCI105383","volume":"45","author":"I. Diamond","year":"1966","unstructured":"Diamond, I., Schmid, R. Experimental bilirubin encephalopathy. J Clin Invest, 1966, 45, 678\u2013689.","journal-title":"J Clin Invest"},{"key":"BF02032282_CR11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/106002807100501202","volume":"5","author":"E.A. Hartshorn","year":"1971","unstructured":"Hartshorn, E.A. Drug interactions: analgesics-salicylates. Drug intelligence and clinical pharmacy, 1971, 5, 388\u2013392.","journal-title":"Drug intelligence and clinical pharmacy"},{"key":"BF02032282_CR12","first-page":"217","volume-title":"Textbook of adverse drug reactions","author":"J. Anderson","year":"1977","unstructured":"Anderson, J. Disorder of metabolism. In: Textbook of adverse drug reactions. Editor: Davies D.M. London-Oxford University Press. 1977, pp. 217\u2013227."},{"key":"BF02032282_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1185\/03007997709108977","volume":"5","author":"P.M. Brooks","year":"1977","unstructured":"Brooks, P.M., Khong, T.K. Flurbiprofen-Aspirin interaction: a double-blind crossover study. Curr Med Res Opin, 1977, 5, 53\u201357.","journal-title":"Curr Med Res Opin"},{"key":"BF02032282_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt1974153247","volume":"15","author":"B. Lindquist","year":"1974","unstructured":"Lindquist, B., Jensen, K.M., Johansson, H., Hansen, T. Effect of administration of aspirin and indomethacin on serum concentration. Clin Pharmacol Ther, 1974, 15, 247\u2013252.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000136516","volume":"12","author":"R.W. Mason","year":"1974","unstructured":"Mason, R.W., McQueen, E.G. Protein-binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate in vitro. Pharmacology, 1974, 12, 12\u201319.","journal-title":"Pharmacology"},{"key":"BF02032282_CR16","first-page":"397","volume":"15","author":"F.O. M\u00fcller","year":"1977","unstructured":"M\u00fcller, F.O., Hundt, H.K.L., M\u00fcller, D.G. Pharmacokinetic and pharmacodynamic implications of long-term administration of nonsteroidal anti-inflammatory agents. Intern J Clin Pharmacol, 1977, 15, 397\u2013402.","journal-title":"Intern J Clin Pharmacol"},{"key":"BF02032282_CR17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/art.1780160508","volume":"16","author":"A. Rubin","year":"1973","unstructured":"Rubin, A., Rodda, B.E., Warrich, P., Gruber, C.M., Ridolfo, A.S. Interaction of aspirin with non-steroidal anti-inflammatory drugs in man. Arthritis Rheum, 1973, 16, 635\u2013645.","journal-title":"Arthritis Rheum"},{"key":"BF02032282_CR18","first-page":"34","volume":"6","author":"E.J. Segre","year":"1974","unstructured":"Segre, E.J., Chaplin, M., Forchielli, E., Runkel, R., Sevelius, H. Naproxen-aspirin interactions in man. Clin Pharmacol Ther, 1974, 6, 34\u2013358.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR19","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/bmj.1.5446.1354","volume":"i","author":"L.P.J. Holt","year":"1965","unstructured":"Holt, L.P.J., Hawkins, C.F. Indomethacin: studies of absorption and of the use of indomethacin suppositories. Br Med J, 1965, i, 1354\u20131356.","journal-title":"Br Med J"},{"key":"BF02032282_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0021-9673(00)89871-4","volume":"153","author":"R.G. Sibeon","year":"1978","unstructured":"Sibeon, R.G., Baber, N.S., Chan, K.K., Baty, D., Orme, M.L'E. A quantitative gas-liquid chromatographic method for the determination of indomethacin in biological fluids. J Chromatogr, 1978, 153, 189\u2013194.","journal-title":"J Chromatogr"},{"key":"BF02032282_CR21","first-page":"225","volume-title":"clinics in rheumatic diseases","author":"J. Levy","year":"1975","unstructured":"Levy, J., Dick, W.C. The detection of change in disease activity in patients with rheumatoid arthritis. In: clinics in rheumatic diseases. Editors: Pearson, C.M., Dick, W.C. Saunders Company Ltd, London Philadelphia Toronto. 1975, 1, 2, pp. 225\u2013243."},{"key":"BF02032282_CR22","first-page":"448","volume-title":"Arthritis and Allied Conditions","author":"T.B. Bayles","year":"1972","unstructured":"Bayles, T.B. Salicylate therapy for rheumatoid arthritis. In: Arthritis and Allied Conditions, 8th ed. Editors: Hollander, J.L., McCarty, D.J. Lea and Febiger, Philadelphia. 1972. 448\u2013454.","edition":"8th ed."},{"key":"BF02032282_CR23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.1780140412","volume":"14","author":"H.E. Paulus","year":"1971","unstructured":"Paulus, H.E., Siegel, M., Mongan, E., Okun, R., Calabro, J.J. Variation of serum concentrations and half-life of salicylate in patients with rheumatoid arthritis. Arthritis Rheum, 1971, 14, 527\u2013532.","journal-title":"Arthritis Rheum"},{"key":"BF02032282_CR24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2125.1975.tb01581.x","volume":"2","author":"T. Gibson","year":"1975","unstructured":"Gibson, T., Zaphiropoulos, G., Grave, J., Widdop, B., Berry, D. Kinetics of salicylate metabolism. Br J Clin Pharmacol, 1975, 2, 233\u2013238.","journal-title":"Br J Clin Pharmacol"},{"key":"BF02032282_CR25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpt1975183350","volume":"18","author":"N. Gupta","year":"1975","unstructured":"Gupta, N., Sarkissian, E., Paulus, H.E Correlation of plateau serum salicylate level with rate of salicylate metabolism Clin Pharmacol Ther, 1975, 18, 350\u2013355.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/cpt1977224410","volume":"22","author":"G.G. Graham","year":"1977","unstructured":"Graham, G.G., Champion, G.D., Day, R.O., Paull, P.D. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther, 1977, 22, 410\u2013420.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR27","first-page":"220","volume":"25","author":"R.O. Day","year":"1979","unstructured":"Day, R.O., Shen, D., Azarnoff, D. Decline of steadystate serum salicylate in rheumatoid arthritis given high-dosage salicylate therapy. Clin Pharmacol Ther, 1979, 25, 220\u2013221.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3109\/03009747509165266","volume":"4","author":"A.L. M\u00e4kel\u00e4","year":"1975","unstructured":"M\u00e4kel\u00e4, A.L., Yrj\u00e4n\u00e4, T., Haapasaari, J. Dosage of salicylates for children with juvenile rheumatoid arthritis. Scand J Rheumatol, 1975, 4, 250\u2013252.","journal-title":"Scand J Rheumatol"},{"key":"BF02032282_CR29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1651-2227.1979.tb05031.x","volume":"68","author":"A.L. M\u00e4kal\u00e4","year":"1979","unstructured":"M\u00e4kal\u00e4, A.L., Yrj\u00e4n\u00e4, T., Mattila, M. Dosage of salicylates for children with juvenile rheumatoid arthritis. Acta Paediatr Scand, 1979, 68, 423\u201330.","journal-title":"Acta Paediatr Scand"},{"key":"BF02032282_CR30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/adc.53.5.381","volume":"53","author":"M. Bardare","year":"1978","unstructured":"Bardare, M., Chislaghi, G.U., Mandelli, M., Sereni, F. Value of monitoring plasma salicylate levels in treating juvenile rheumatoid arthritis: observations in 42 cases. Arch Dis Child, 1978, 53, 381\u2013385.","journal-title":"Arch Dis Child"},{"key":"BF02032282_CR31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.1973.03230020014004","volume":"226","author":"E. Mongan","year":"1973","unstructured":"Mongan, E., Kelly, P., Nies, K., Porter, W., Paulus, H. Tinnitus as an indication of therapeutic serum salicylate levels JAMA, 1973, 226, 142\u2013145.","journal-title":"JAMA"},{"key":"BF02032282_CR32","first-page":"957","volume-title":"Pharmacologie clinique. Bases de la th\u00e9rapeutique","author":"J.P. Giroud","year":"1978","unstructured":"Giroud, J.P., Brouilhet, H. Anti-inflammatoires non steroidiens. In: Pharmacologie clinique. Bases de la th\u00e9rapeutique. Editors: Giroud J.P., Math\u00e9, G., Meyniel, G., Expansion scientifique fran\u00e7aise, Paris. 1978, vol 1, pp. 957\u2013994."},{"key":"BF02032282_CR33","first-page":"36","volume":"9","author":"V.H. Saggers","year":"1972","unstructured":"Saggers, V.H., Chasseaud, L.F., Cooper, A.J. Plasma concentrations, duration of analgesia and bioavailability of micro-encapsulated aspirin. Clinical Trials Journal, 1972, 9, 36\u201338.","journal-title":"Clinical Trials Journal"},{"key":"BF02032282_CR34","first-page":"347","volume":"8","author":"E.P. Frenkel","year":"1968","unstructured":"Frenkel, E.P., McCall, M.S., Douglas, C.C., Eisenberg's. Fecal blood loss following aspirin and coated aspirin microspherule administration. J Clin Pharmacol, 1968, 8, 347\u2013351.","journal-title":"J Clin Pharmacol"},{"key":"BF02032282_CR35","first-page":"210","volume":"6","author":"H. Mielants","year":"1979","unstructured":"Mielants, H., Veys, E.M., Verbruggen, G., Schelstraete, K. Salicylate-induced gastrointestinal bleeding: Comparison between soluble buffered, enteric-coated and intravenous administration. J Rheumatol, 1979, 6, 210\u2013218.","journal-title":"J Rheumatol"},{"key":"BF02032282_CR36","doi-asserted-by":"crossref","unstructured":"Macpherson, C.R., Milne, M.D., Evans, B.M. The excretion of salicylate. Br J Pharmacol, 195, 10, 484\u2013489.","DOI":"10.1111\/j.1476-5381.1955.tb00109.x"},{"key":"BF02032282_CR37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.217.1.81c","volume":"217","author":"G. Levy","year":"1971","unstructured":"Levy, G., Leonards, J.R. Urine pH and salicylate therapy. JAMA, 1971, 217, 81.","journal-title":"JAMA"},{"key":"BF02032282_CR38","first-page":"346","volume":"109","author":"J.J. Barns","year":"1953","unstructured":"Barns, J.J., Rose, R.K., Chenkin, T., Goldman, A., Schulbert, A., Brodie, B.B. The physiological disposition of phenylbutazone in man and a method for its estimation in biological fluids. J Pharmacol Exp Ther, 1953, 109, 346\u2013357.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02032282_CR39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2125.1976.tb00587.x","volume":"3","author":"M.L.E. Orme","year":"1976","unstructured":"Orme, M.L'E., Holt, P.J., Hughes, G.R., Bulpitt, C.J., Draffan, G.H., Thorgeirsson, S., Williams, F., Davies, D.S. Plasma concentration of phenyl-butazone and its therapeutic effects. Studies in patients with rheumatoid arthritis. Br J Clin Pharmacol, 1976, 3, 185\u2013191.","journal-title":"Br J Clin Pharmacol"},{"key":"BF02032282_CR40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00003088-197803050-00003","volume":"3","author":"J. Aarbakke","year":"1978","unstructured":"Aarbakke, J. Clinical pharmacokinetics of phenyl-butazone. Clin Pharmacokinet, 1978, 3, 369\u2013380.","journal-title":"Clin Pharmacokinet"},{"key":"BF02032282_CR41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(54)90874-0","volume":"i","author":"E. Bruck","year":"1954","unstructured":"Bruck, E., Fearnley, M.E., Meanock, I., Patley, H. Phenylbutazone therapy: relation between the toxic and therapeutic effects and the blood level. Lancet, 1954, i, 225\u2013228.","journal-title":"Lancet"},{"key":"BF02032282_CR42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.1975.tb00553.x","volume":"2","author":"P.M. Brooks","year":"1975","unstructured":"Brooks, P.M., Walker, J.J., Dick, W.C., Anderson, J.A., Fowler, P.D. Phenylbutazone: a clinico-pharmacological study in rheumatoid arthritis. Br J Clin Pharmacol, 1975, 2, 437\u2013442.","journal-title":"Br J Clin Pharmacol"},{"key":"BF02032282_CR43","first-page":"621","volume":"40","author":"H.A. Bird","year":"1981","unstructured":"Bird, H.A., Lowe, J.R., Leatham, P.A., Downie, W.W., Fowler, P.D., Wright, V. A phenylbutazone dose-finding study. Ann Rheum Dis, 1981, 40, 621\u2013622.","journal-title":"Ann Rheum Dis"},{"key":"BF02032282_CR44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.3.5926.313","volume":"3","author":"J. Cuningham","year":"1974","unstructured":"Cuningham, J., Leyland, M.J., Delamere, I.W., Price-Evans, D.A. Acetanilide oxidation in phenyl-butazone associated hypoplastic anaemia. Br Med J, 1974, 3, 313\u2013317.","journal-title":"Br Med J"},{"key":"BF02032282_CR45","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.38.2.128","volume":"38","author":"N.S. Baber","year":"1979","unstructured":"Baber, N.S., Halliday, L.D.C., Vandenheuvel, W.J.A., Walker, R.W., Sibeon, R.G., Keenan, J.P., Littler, T.R., Orme, M.L'E. A study of indomethacin in rheumatoid arthritis. Clinical effects, pharmacokinetics and platelet studies in responders and non-responders. Ann Rheum Dis, 1979, 38, 128\u2013137.","journal-title":"Ann Rheum Dis"},{"key":"BF02032282_CR46","first-page":"36","volume":"suppl. 9","author":"M.L.E. Orme","year":"1980","unstructured":"Orme, M.L'E., Baber, N.S., Halliday, L., Sibeon, R.G., Littler, T.R. Flurbiprofen and Indomethacin in rheumatoid arthritis: studies in responders and non-responders. Br J Clin Pract, 1980, suppl. 9, 36\u201342.","journal-title":"Br J Clin Pract"},{"key":"BF02032282_CR47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF00570161","volume":"17","author":"R. Ekstrand","year":"1980","unstructured":"Ekstrand, R., Alvan, G., Orme, M.L'E., Lewander, R., Palmer, L., Sorby, B. Double-blind dose response study of indomethacin in rheumatoid arthritis. Eur J Clin Pharmacol, 1980, 17, 437\u2013442.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF02032282_CR48","first-page":"34","volume":"Suppl 11","author":"H. Turakka","year":"1974","unstructured":"Turakka, H., Airaksinnen, M.M. Biopharmaceutical assessment of phenylbutazone and indomethacin preparations. Ann Clin Res, 1974, Suppl 11, 34\u201341.","journal-title":"Ann Clin Res"},{"key":"BF02032282_CR49","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt1975183364","volume":"18","author":"G. Avlan","year":"1975","unstructured":"Avlan, G., Orme, M.L'E., Bertilsson, L., Eksrand, R., Palmer, L. The pharmacokinetics of indomethacin in man. Clin Pharmacol Ther, 1975, 18, 364\u2013373.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00615406","volume":"20","author":"J. Clench","year":"1981","unstructured":"Clench, J., Reinberg, A., Dziewanowska, Z., Ghata, J., Smolensky, N. Circadian changes in the bioavalability and effects of indomethacin in healthy subjects. Eur J Clin Pharmacol, 1981, 20, 359\u2013369.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF02032282_CR51","first-page":"409","volume":"17","author":"A. Markiewicz","year":"1979","unstructured":"Markiewicz, A., Semenovicz, K. Time dependent changes in the pharmacokinetics of aspirin. Int J Clin Pharmacol Ther Toxicol, 1979, 17, 409\u2013411.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"BF02032282_CR52","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3181\/00379727-124-31863","volume":"124","author":"A. Reinberg","year":"1967","unstructured":"Reinberg, A., Zagula-Mally, Z.W., Ghata, J., Halberg, F. Circadian rythm in duration of salicylate excretion referred to phase of excretory rythms and routine. Proc Soc Exp Biol Med,(N.Y.), 1967, 124, 826\u2013832.","journal-title":"Proc Soc Exp Biol Med,(N.Y.)"},{"key":"BF02032282_CR53","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/cpt1978236658","volume":"23","author":"A. Rane","year":"1978","unstructured":"Rane, A., Oelz, O., Frolich, J.E., Seyberth, H.W., Sweetman, B.J., Watson, J.T., Wilkinson, G.R., Oates, J.A. Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther, 1978, 23, 658\u2013668.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0049-0172(75)90023-2","volume":"5","author":"J.P. Famaey","year":"1975","unstructured":"Famaey, J.P., Brooks, P.M., Dick, W.C. Biological effects of nonsteroidal anti-inflammatory drugs. Semin Arthritis Rheum, 1975, 5, 63\u201381.","journal-title":"Semin Arthritis Rheum"},{"key":"BF02032282_CR55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1056\/NEJM198107093050203","volume":"305","author":"A.R. Brash","year":"1981","unstructured":"Brash, A.R., Hickey, D.E., Graham, T.P., Stahlman, M.T., Oates, J.A., Cotton, R.B. Pharmacokinetics of indomethacin in the neonate: Relation of plasma indomethacin levels to response of ductus arteriosus. New Engl J Med, 1981, 305, 67\u201372.","journal-title":"New Engl J Med"},{"key":"BF02032282_CR56","first-page":"13.1","volume-title":"The immune system and inflammation mechanisms: immunosuppressive and anti-inflammatory drugs","author":"W.C. Bowman","year":"1980","unstructured":"Bowman, W.C., Rand, M.J. Textbook of pharmacology. Chapter 13. The immune system and inflammation mechanisms: immunosuppressive and anti-inflammatory drugs., 2nd ed. Blackwell Scientific Publication, Oxford,London, Edinburgh, Melbourne. 1980, pp. 13.1\u201313.35.","edition":"2nd ed."},{"key":"BF02032282_CR57","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2125.1974.tb00254.x","volume":"1","author":"P.M. Brooks","year":"1974","unstructured":"Brooks, P.M., Bell, M.A., Sturrock, A.D., Famaey, J.P., Dick, W.C. The clinical significance of indomethacin-probenecid interaction. Br J Clin Pharmacol, 1974, 1, 287\u2013290.","journal-title":"Br J Clin Pharmacol"},{"key":"BF02032282_CR58","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/clpt.1981.27","volume":"29","author":"G. Tomson","year":"1981","unstructured":"Tomson, G., Lunell, N.O., Oliw, E., Rane, A. Relation of naproxen kinetics to effect on platelet prostaglandin release in man and dysmenorrhoea in women. Clin Pharmacol Ther, 1981, 29, 168\u2013173.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02032282_CR59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2125.1980.tb01753.x","volume":"10","author":"H. Sevelius","year":"1980","unstructured":"Sevelius, H., Runkel, R., Segre, E., Bloomfield, S.S. Bioavaibility of naproxen sodium and its relationship to clinical analgesic effects. Br J Clin Pharmacol, 1980, 10, 259\u2013263.","journal-title":"Br J Clin Pharmacol"},{"key":"BF02032282_CR60","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/jps.2600630530","volume":"63","author":"D.G. Kaiser","year":"1974","unstructured":"Kaiser, D.G., Glenn, E.M. Correlation of plasma ibuprofen levels with biological activity. J Pharm Sci, 1974, 63, 784\u2013786.","journal-title":"J Pharm Sci"},{"key":"BF02032282_CR61","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/jps.2600640514","volume":"64","author":"G.J. Vangiessen","year":"1975","unstructured":"Vangiessen, G.J., Kaiser, D.G. GLC determination of ibuprofen (dl-2-(p-isobutylphenyl) propionic acid) enantiomers in biological specimens. J Pharm Sci, 1975, 64, 798\u2013801.","journal-title":"J Pharm Sci"},{"key":"BF02032282_CR62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/03009748109095330","volume":"Suppl. 39","author":"M.L.E. Orme","year":"1981","unstructured":"Orme, M.L'E., Baber, N.S., Keenan, J.P., Halliday, L., Sibeon, R.G., Littler, T. Pharmacokinetics and biochemical effects in responders and non-responders to non-steroidal anti-inflammatory drugs. Scand J Rheumatol, 1981, Suppl. 39, 19\u201327.","journal-title":"Scand J Rheumatol"},{"key":"BF02032282_CR63","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1185\/03007997709108982","volume":"5","author":"E.C. Huskisson","year":"1977","unstructured":"Huskisson, E.C., Scott, P.J., Boyle, S., Patrick, M. Flurbiprofen at night. Curr Med Res Opin, 1977, 5, 85\u201387.","journal-title":"Curr Med Res Opin"},{"key":"BF02032282_CR64","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2125.1977.tb00797.x","volume":"4","author":"H.A. Capell","year":"1977","unstructured":"Capell, H.A., Konetschnick, B., Glass, R.C. Anti-inflammatory responders and non-responders: a clinicopharmacological study of flurbiprofen. Br J Clin Pharmacol, 1977, 4, 623\u2013624.","journal-title":"Br J Clin Pharmacol"},{"key":"BF02032282_CR65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00607149","volume":"20","author":"R.A. Upton","year":"1981","unstructured":"Upton, R.A., Williams, R.L., Guntert, T.W., Buskin, J.N., Reigelman, S. Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay. Eur J Clin Pharmacol, 1981, 20, 127\u2013133.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF02032282_CR66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/ard.32.5.433","volume":"32","author":"H.W. Emori","year":"1973","unstructured":"Emori, H.W., Champion, G.D., Bluestone, R., Paulus, H. Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Ann Rheum Dis, 1973, 32, 433\u2013435.","journal-title":"Ann Rheum Dis"},{"key":"BF02032282_CR67","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1185\/03007997509114776","volume":"3","author":"G.M. Thomas","year":"1975","unstructured":"Thomas, G.M., Rees, P., Dippy, J.E., Maddock, J. Simultaneous pharmacokinetics of alclofenac in serum and synovial fluid in patients with rheumatoid arthritis. Curr Med Res Opin, 1975, 3, 264\u2013267.","journal-title":"Curr Med Res Opin"},{"key":"BF02032282_CR68","series-title":"Clinics in Rheumatic Diseases","first-page":"427","volume-title":"Anti-Rheumatic Drugs","author":"P.D. Fowler","year":"1979","unstructured":"Fowler, P.D. Voltarol: Diclofenac sodium. In: Anti-Rheumatic Drugs. Editor: Huskisson, E.C. Clinics in Rheumatic Diseases, 1979, Saunders Company Ltd, London Philadelphia Toronto, vol. no 2, pp. 427\u2013464."},{"key":"BF02032282_CR69","doi-asserted-by":"crossref","unstructured":"Glass, R.C., Swannell, A.J. Concentration of ibuprofen in serum and synovial fluid from patients with arthritis. Br J Clin Pharmacol, 1978, 6, 453 p.","DOI":"10.1111\/j.1365-2125.1978.tb04624.x"},{"key":"BF02032282_CR70","first-page":"3","volume":"suppl 9","author":"T.M. Chalmers","year":"1980","unstructured":"Chalmers, T.M., Glass, R.C., Marchant, B. Concentrations of flurbiprofen in serum and synovial fluids from patients with active rheumatoid disease. Br J Clin Pract., 1980, suppl 9, 3\u20135.","journal-title":"Br J Clin Pract."},{"key":"BF02032282_CR71","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1185\/03007997509113681","volume":"3","author":"W.S. Mitchell","year":"1975","unstructured":"Mitchell, W.S., Scott, P., Kennedy, A.C., Brooks, P.M., Templeton, R., Jeffries, M. Clinico-pharmacological studies on ketoprofen (Orudis). Curr Med Res Opin, 1975, 3, 423\u2013430.","journal-title":"Curr Med Res Opin"},{"key":"BF02032282_CR72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/03009747709095441","volume":"6","author":"S. Jalava","year":"1977","unstructured":"Jalava, S., Saarimaa, H., Anttila, M., Sundquist, H. Naproxen concentrations in serum, synovial fluid and synovium. Scand J Rheumatol, 1977, 6, 155\u2013158.","journal-title":"Scand J Rheumatol"},{"key":"BF02032282_CR73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000406530","volume-title":"Articular Synovium","author":"R.J. Desiraju","year":"1982","unstructured":"Desiraju, R.J., Nayak, R.K., Furst, D.E., Paulus, H.E. Steady state serum and synovial fluid concentrations of tolmetin and its metabolite in arthritic patients. In: Articular Synovium, Editor: Franchimont P., Karger, Basel, 1982, pp. 177\u2013184."},{"key":"BF02032282_CR74","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/art.1780100405","volume":"10","author":"S.D. Sholkoff","year":"1967","unstructured":"Sholkoff, S.D., Eyring, E.J., Rowland, M., Riegelman, S. Plasma and synovial fluid concentrations of aspirin in patients with rheumatoid arthritis. Arthritis Rheum., 1967, 10, 348\u2013351.","journal-title":"Arthritis Rheum."},{"key":"BF02032282_CR75","first-page":"17","volume":"6","author":"A. Soren","year":"1977","unstructured":"Soren, A. Dissociation of acetylsalicylic in blood and joint fluid. Scand J Rheumatol, 1977, 6, 17\u201322.","journal-title":"Scand J Rheumatol"},{"key":"BF02032282_CR76","first-page":"1211","volume-title":"Drug treatment","author":"R.C. Heel","year":"1980","unstructured":"Heel, R.C., Avery, G.S. Drug data information. In: Drug treatment, 2nd ed. Editor: Avery, G.S. Adis Press, Australia, 1980, pp. 1211\u20131222.","edition":"2nd ed."}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02032282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02032282\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02032282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T20:20:05Z","timestamp":1586377205000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02032282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,6]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1985,6]]}},"alternative-id":["BF02032282"],"URL":"https:\/\/doi.org\/10.1007\/bf02032282","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,6]]}}}